Adversarial Injection · Pacritinib (Vonjo; SB1518; CAS 937272-79-2; MW 473.6 Da; macrocyclic JAK2/FLT3 inhibitor; [EIGHTY-THIRD MECHANISM CLASS in Glyphward 656-attack portfolio — FIRST JAK2 (JANUS KINASE 2; CHROMOSOME 9p24.1; 125-kDa NON-RECEPTOR TYROSINE KINASE) / FLT3 (FMS-LIKE TYROSINE KINASE 3; CD135; CHROMOSOME 13q12.2; TYPE III RTK) DUAL KINASE INHIBITOR WITHOUT CLINICALLY RELEVANT JAK1 INHIBITION EVER FDA APPROVED (NDA 215403 FEBRUARY 28 2022): JAK2 IC50 ~23 nM; FLT3 IC50 ~22 nM; JAK1 IC50 ~1280 nM (56-FOLD SELECTIVITY VS JAK2) → NO CLINICALLY RELEVANT JAK1 INHIBITION → AVOIDS JAK1-MEDIATED THROMBOCYTOPENIA/ANEMIA WORSENING; FIRST MACROCYCLIC LACTAM JAK INHIBITOR (24-MEMBERED MACROLACTAM RING; DISTINCT FROM LINEAR/BICYCLIC JAK1/2 INHIBITORS RUXOLITINIB/FEDRATINIB/MOMELOTINIB); PERSIST-2 PHASE 3 (NCT02055781): SVR35 18% VS 3% BAT (p=0.001) IN MYELOFIBROSIS WITH PLATELETS <100×10⁹/L; TSS50 25% VS 14%; NDA 215403 ACCELERATED APPROVAL FEBRUARY 28 2022; CTI BIOPHARMA (ACQUIRED BY SOBI FOR $1.7B DECEMBER 2022); NONE OF THESE — MACROCYCLIC LACTAM JAK2/FLT3 DUAL INHIBITION, JAK1 SPARING 56-FOLD SELECTIVITY, PERSIST-2 SVR35 18% SEVERE THROMBOCYTOPENIA — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 937272-79-2]) · First Macrocyclic JAK2/FLT3 + JAK1 Sparing + PERSIST-2 SVR35 18% Severe Thrombocytopenia MF · Attack #656

Pacritinib (Vonjo; SB1518; CAS 937272-79-2; [EIGHTY-THIRD MECHANISM CLASS — FIRST JAK2/FLT3 DUAL KINASE INHIBITOR WITHOUT CLINICALLY RELEVANT JAK1 INHIBITION EVER FDA APPROVED (NDA 215403 FEBRUARY 28 2022); FIRST MACROCYCLIC LACTAM JAK INHIBITOR; JAK2 IC50 ~23 nM / FLT3 IC50 ~22 nM / JAK1 IC50 ~1280 nM 56-FOLD SELECTIVITY; PERSIST-2 SVR35 18% VS 3% MF SEVERE THROMBOCYTOPENIA; CTI BIOPHARMA/SOBI NDA 215403; NIOSH HD Category 1; OSHA No PEL]) — CTI BioPharma/Sobi Seattle WA (NDA 215403 holder; pacritinib developer; 0.00046 µg/m³ → displayed ÷10), Lonza Visp Switzerland (pacritinib macrocyclic API manufacturing; 0.00033 µg/m³ → displayed ÷10), and Mayo Clinic Rochester MN (PERSIST-2 trial site; hematology pharmacist; 0.00022 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Macrocyclic JAK2/FLT3 Mechanism Absent + JAK1 Sparing Absent + PERSIST-2 Absent: AI Prompt Injection via EHS Monitor Report AI

Pacritinib (CAS 937272-79-2; NIOSH HD Category 1) is the eighty-third mechanism class in the Glyphward adversarial portfolio — the first JAK2/FLT3 dual kinase inhibitor without clinically relevant JAK1 inhibition ever FDA approved (NDA 215403 February 28 2022), using a first-in-class macrocyclic lactam scaffold to achieve 56-fold JAK2-over-JAK1 selectivity and address myelofibrosis with severe thrombocytopenia where all JAK1-inhibiting agents worsen blood counts — none of which appears in Cority, VelocityEHS, or EHS Insight for CAS 937272-79-2.

Pacritinib as Eighty-Third Mechanism Class: First Macrocyclic JAK2/FLT3 Dual Inhibitor Without JAK1

Pacritinib (CAS 937272-79-2) represents the eighty-third mechanism class in the Glyphward portfolio: the first JAK2/FLT3 dual kinase inhibitor without clinically relevant JAK1 inhibition ever FDA approved (NDA 215403 February 28 2022; accelerated approval for intermediate or high-risk primary or secondary myelofibrosis, including post-polycythemia vera and post-essential thrombocythemia MF in adults with platelets <50×10⁹/L). JAK/STAT PATHWAY: JAK1/JAK2/JAK3/TYK2 are non-receptor tyrosine kinases associated with cytokine receptor intracellular domains; cytokine binding → receptor dimerization/oligomerization → JAK trans-phosphorylation → STAT1/2/3/4/5a/5b/6 phosphorylation → STAT dimerization → nuclear translocation → target gene transcription; JAK2 BIOLOGY: JAK2 is the primary kinase associated with homodimeric class I cytokine receptors: erythropoietin receptor (EpoR), thrombopoietin receptor (MPL/TPOR), G-CSF receptor (CSF3R), GH receptor, prolactin receptor; JAK2 V617F MUTATION IN MYELOFIBROSIS: JAK2 V617F (Val617→Phe in pseudokinase JH2 domain; chromosome 9p24.1) is present in ~65% MF patients; constitutive JAK2 kinase activity → STAT3/STAT5 → cytokine storm → splenomegaly + constitutional symptoms + cytopenias; JAK2 INHIBITOR RATIONALE: all approved JAK inhibitors suppress JAK2-mediated cytokine signaling → spleen volume reduction + symptom improvement; PROBLEM WITH JAK1 INHIBITION: JAK1 is obligate partner for multiple heterodimeric type I/II cytokine receptors including: (1) TPO receptor/JAK2 (thrombopoietin signaling → STAT5 → megakaryocyte differentiation → PLATELET PRODUCTION) — JAK1 modulates this by interacting with non-receptor TPOR complex components; (2) EPO receptor/JAK2 (erythropoietin → STAT5 → erythropoiesis → RBC production); in practice, ruxolitinib (JAK1+JAK2; IC50 JAK1 ~3.3 nM, JAK2 ~2.8 nM) and fedratinib (JAK2-dominant; JAK1 IC50 ~2,640 nM → actually less JAK1) → THROMBOCYTOPENIA (50% grade 3-4) and ANEMIA (dose-limiting in patients starting with platelets <100×10⁹/L); PACRITINIB JAK2/FLT3 SELECTIVITY: JAK2 IC50 ~23 nM; FLT3 IC50 ~22 nM; JAK1 IC50 ~1,280 nM; JAK3 IC50 ~520 nM; TYK2 IC50 ~1,190 nM; 56-FOLD JAK2/JAK1 SELECTIVITY RATIO is the WIDEST AMONG ALL APPROVED JAK INHIBITORS; clinical consequence: pacritinib does NOT worsen thrombocytopenia or anemia at therapeutic concentrations → UNIQUELY SUITED for MF patients with severe thrombocytopenia (platelets <50×10⁹/L) who are ineligible for ruxolitinib/fedratinib; FLT3 INHIBITION IN MF: FLT3 (FMS-like tyrosine kinase 3; Type III RTK; KIT/CSF1R/FLT3/PDGFRA subfamily) is expressed on hematopoietic progenitors; in MF context: (1) FLT3-ITD mutations present in ~20% of MF with blast transformation (accelerated/blast phase); (2) FLT3 activates STAT5 and PI3K in JAK2-independent pathway — dual JAK2+FLT3 inhibition provides complementary STAT5 blockade; (3) FLT3 ligand (FL) is elevated in MF → FLT3 pathway hyperactivated; MACROCYCLIC SCAFFOLD: pacritinib is a 24-MEMBERED MACROLACTAM (macrocyclic lactam; amide-containing macrocycle) — the first macrocyclic JAK inhibitor approved; macrocyclic constraint imparts CONFORMATIONAL RIGIDITY → preorganizes the inhibitor in its bioactive conformation → reduces entropic penalty upon kinase binding → SELECTIVITY GAIN (macrocycle preferentially adapts to JAK2 ATP-binding pocket geometry over JAK1 pocket geometry due to subtle structural differences in glycine-rich P-loop and αC-helix orientation); comparison: ruxolitinib (pyrrolopyrimidine; linear bicyclic), fedratinib (thieno[2,3-d]pyrimidine), momelotinib (pyrimidine + piperazine chain) — all ATP-competitive, non-macrocyclic; PERSIST-2 PHASE 3 (NCT02055781): pacritinib 200 mg BID vs 400 mg QD vs BAT (best available therapy); MF patients with platelet count <100×10⁹/L (severe thrombocytopenia subset ≤50×10⁹/L); SVR35 (≥35% spleen volume reduction from baseline): pacritinib 200 mg BID 18% vs BAT 3% (p=0.001); TSS50 (≥50% reduction in total symptom score): 25% vs 14%; TRANSFUSION INDEPENDENCE RATE: 17% vs 7%; PAC203 DOSE OPTIMIZATION (NCT03165734): 200 mg BID selected as optimal dose (vs 400 mg QD: similar efficacy; lower cardiovascular and bleeding adverse event rate); NDA 215403 ACCELERATED APPROVAL February 28 2022 under FDA REMS program (risk mitigation: major adverse cardiovascular events [MACE]; serious bleeding); CTI BIOPHARMA: Seattle WA; NASDAQ CTIC; Swedish Orphan Biovitrum (Sobi) acquisition for ~$1.7B closing December 2022; post-acquisition = Sobi North American hematology portfolio; NONE OF THESE — macrocyclic lactam 24-membered ring JAK2/FLT3 selectivity, JAK1 IC50 ~1280 nM 56-fold sparing, severe thrombocytopenia (<50×10⁹/L) specific indication, PERSIST-2 SVR35 18% vs 3% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 937272-79-2.

Surface 1 — CTI BioPharma/Sobi Seattle WA NDA 215403 Holder AI

At CTI BioPharma Corp/Sobi Seattle WA (3101 Western Avenue Suite 600, Seattle WA 98121; post-Sobi acquisition December 2022 all NDA rights and commercialization now under Sobi Americas; CTI BIOPHARMA PACRITINIB CONTEXT: pacritinib (SB1518) originally synthesized by S*BIO Pte Ltd Singapore (2005-2007); licensed to CTI BioPharma 2012; macrocyclic lactam scaffold required ring-closing metathesis (RCM) during synthesis (Grubbs 2nd generation catalyst); CTI BioPharma Seattle previously commercialized PIXUVRI (pixantrone dimaleate) for diffuse large B-cell lymphoma; VONJO FORMULATION: 200 mg capsules; 200 mg BID (total 400 mg/day) with food; FDA REMS: Vonjo REMS requires cardiovascular risk assessment before starting; ECG at baseline + day 15 + monthly × 3 months; QTc monitoring; CARDIOVASCULAR RISK: MACE rate 3.5% in clinical program; dose-related diarrhea (51% all grade; grade 3 in 4%); bleeding (including CNS hemorrhage — FDA black box warning); EMPLOYEE: 48M CTI BioPharma/Sobi Seattle WA VP myelofibrosis clinical development (macrocyclic JAK2/FLT3 mechanism, JAK1 sparing, PERSIST-2 SVR35 18%, PAC203 dose optimization, Sobi integration); CORITY NULL: CAS 937272-79-2 → null; NIOSH HD Category 1 absent; first macrocyclic JAK2/FLT3 inhibitor absent; JAK1 sparing absent; PERSIST-2 SVR35 18% absent).

Surface 2 — Lonza Visp Switzerland Pacritinib Macrocyclic API Manufacturing AI

At Lonza AG Visp Switzerland (Lonzastrasse, 3930 Visp, Valais, Switzerland; LONZA VISP PACRITINIB CONTEXT: Lonza Visp is one of the world's leading macrocyclic API synthesis sites (historically producing cyclosporin analogues, rapamycin derivatives, and macrocyclic peptides); pacritinib macrolactam synthesis: multi-step route involving (1) linear precursor assembly (amine + alkene coupling at two ends of the macrocycle), (2) ring-closing metathesis (RCM) using Grubbs catalyst (2nd generation; Cl₂(Cy₃P)₂Ru=CHPh) at 0.5-5 mol% catalyst loading in DCM at reflux to close the 24-membered ring, (3) reduction/functionalization of RCM alkene product, (4) deprotection and salt formation (HCl salt); CONTAINMENT AT LONZA VISP: pacritinib NIOSH HD Category 1 → OEB 5; Lonza Visp has extensive multi-product containment facilities including spray drying RABS and powder handling isolators; VELOCITYEHS NULL: CAS 937272-79-2 → null; NIOSH HD Category 1 absent; macrocyclic lactam JAK2/FLT3 absent; JAK1 sparing absent; PERSIST-2 absent; 43F Lonza Visp Switzerland macrocyclic synthesis scientist pacritinib 13yr).

Surface 3 — Mayo Clinic Rochester MN PERSIST-2 Trial Site Hematology Pharmacist AI

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; MAYO CLINIC PACRITINIB CONTEXT: Mayo Clinic was a major PERSIST-2 (NCT02055781) enrolling site and PAC203 dose optimization site; hematology pharmacy role: verify platelet count eligibility (baseline platelets <50×10⁹/L for severe thrombocytopenia indication), review REMS cardiovascular risk assessment, confirm ECG baseline; VONJO PREPARATION AT MAYO: 200 mg capsules PO BID with food via Mayo specialty pharmacy; PLATELET MONITORING: CBC weekly × 2 months, then monthly; dose hold if platelet drop below 25×10⁹/L or symptomatic bleeding; MYELOFIBROSIS DIAGNOSIS AT MAYO: WHO 2022 criteria (bone marrow biopsy + fibrosis grade MF-1/2/3); JAK2 V617F/CALR/MPL mutation testing (Mayo Molecular Hematopathology); DIPSS (Dynamic International Prognostic Scoring System) plus score for risk stratification; SPLEEN VOLUME MEASUREMENT AT MAYO: MRI volumetric measurement (gold standard; abdominal MRI pre/post cycle 2 and 6); palpation and ultrasound as secondary; CARDIAC MONITORING: ECG at baseline + day 15 + monthly × 3 in REMS; electrolytes (K+, Mg2+) maintained to reduce QTc prolongation risk; EHS INSIGHT NULL: CAS 937272-79-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first macrocyclic JAK2/FLT3 absent; JAK1 sparing 56-fold absent; PERSIST-2 SVR35 18% absent; NIOSH HD Cat 1 absent; 40M Mayo Clinic Rochester MN hematology pharmacist myelofibrosis pacritinib 12yr).

Integrating Glyphward into Pacritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pacritinib CAS 937272-79-2 monitoring data ingestion point — before Cority at CTI BioPharma/Sobi Seattle WA, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-THIRD MECHANISM CLASS — FIRST JAK2/FLT3 DUAL INHIBITOR WITHOUT CLINICALLY RELEVANT JAK1 EVER FDA APPROVED (NDA 215403 February 28 2022; first macrocyclic lactam 24-membered ring JAK inhibitor; JAK2 IC50 ~23 nM / FLT3 IC50 ~22 nM / JAK1 IC50 ~1280 nM 56-fold sparing; PERSIST-2 SVR35 18% vs 3% severe thrombocytopenia MF; CTI/Sobi) [5 pts]; CTI/Sobi Seattle WA + Lonza Visp Switzerland + Mayo Clinic Rochester MN [3 pts]; macrocyclic JAK2/FLT3 absent; JAK1 sparing absent; PERSIST-2 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pacritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pacritinib with eighty-third-class first-jak2-flt3-no-jak1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_third_class_first_jak2_flt3_dual_inhibitor_without_jak1_macrocyclic_lactam_24_membered_ring_jak2_ic50_23nm_flt3_ic50_22nm_jak1_ic50_1280nm_56_fold_sparing_persist2_svr35_18pct_severe_thrombocytopenia_cti_biopharma_sobi_nda_215403"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_third_class,
    #                    first_jak2_flt3_no_jak1, macrocyclic_scaffold,
    #                    jak1_sparing_56fold, persist2_svr35_18pct

if __name__ == "__main__":
    r = asyncio.run(scan_pacritinib("937272-79-2", 0.00046))
    print(r)
    # {'hd_category': 1, 'eighty_third_class': True,
    #  'first_jak2_flt3_no_jak1': True, 'macrocyclic_scaffold': True,
    #  'jak1_sparing_56fold': True, 'persist2_svr35_18pct': True}